SI-591

a cathepsin K inhibitor; structure in first source

Also Known As:

N-(1-(((3-((hexahydro-2-oxo-1H-azepin-3-yl)amino)-1-(1-methylethyl)-2,3-dioxopropyl)amino)carbonyl)cyclohexyl)-2-furancarboxamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Postmenopausal Osteoporosis 12/01/2015 - "Therefore, SI-591, a novel cathepsin K inhibitor, could be a promising agent for the treatment of postmenopausal osteoporosis."
2.	Bone Resorption 12/01/2015 - "These results suggest that SI-591 inhibits bone resorption without affecting osteoblast maturation. " 12/01/2015 - "SI-591 also decreased the level of CTX-I, a bone resorption marker, which was released from osteoclasts in vitro in a dose-dependent manner. " 12/01/2015 - "The mobilization of calcium from the bones to the blood stream is known to increase in rats fed with a low calcium diet; SI-591 inhibited this increase in serum calcium level at an oral dose of 3mg/kg. Furthermore, SI-591 significantly decreased the level of CTX-I and DPD, bone resorption markers, at oral doses of 10mg/kg or less in ovariectomized rats, while it did not affect the level of BGP, a bone formation marker. "